Dr. Frances Oldham Kelsey blocked the U.S. distribution of thalidomide in the early 1960s, a regulatory decision that largely spared the United States from an epidemic of severe birth defects seen across Europe. Working as a medical reviewer for the U.S. Food and Drug Administration (FDA), Kelsey demanded rigorous safety data before approving the sedative for pregnant women, resisting intense commercial pressure from pharmaceutical manufacturer Richardson-Merrell.
The Regulatory Battle Over Thalidomide Approval
Synthesized in 1954 by the Swiss pharmaceutical firm Ciba, thalidomide was licensed to the German company Chemie Grünenthal, which marketed it in 1957 as a safe remedy for anxiety, insomnia, and morning sickness. Richardson-Merrell sought U.S. distribution rights in 1960 under the brand name Kevadon. According to FDA historical records, the application was assigned to Dr. Frances Oldham Kelsey, a pharmacologist and physician who had recently joined the agency.
Kelsey refused to rubber-stamp the application. She flagged a lack of clinical trial data demonstrating the drug’s safety for pregnant patients and noted troubling reports from Europe regarding peripheral neuritis, a neurological side effect involving nerve inflammation in the hands and feet. Despite repeated appeals and pressure from company executives, Kelsey maintained her block throughout 1960 and 1961.
European Tragedy and the Phocomelia Crisis
While the drug remained stalled in the American regulatory pipeline, it was sold over-the-counter or prescribed widely across West Germany, the United Kingdom, Canada, and dozens of other countries. By 1961, pediatricians began noticing a sharp surge in rare, severe congenital malformations—most notably phocomelia, a condition characterized by shortened or absent limbs, alongside severe damage to eyes, ears, hearts, and digestive tracts.
Australian obstetrician Dr. William McBride and German pediatrician Dr. Widukind Lenz independently linked the cluster of birth defects to maternal use of thalidomide during early pregnancy. Chemie Grünenthal withdrew the drug from the market in November 1961, followed by international recalls. Historians estimate that thalidomide caused more than 10,000 children worldwide to be born with severe malformations, with thousands more pregnancies ending in miscarriage or stillbirth.
Impact on American Drug Safety Legislation
In the United States, where Kelsey’s skepticism had kept the drug out of commercial distribution, only a small number of infants were affected—mostly children of physicians who had obtained investigational supplies before clinical trials closed. News of Kelsey’s vigilance transformed public and political perception of the FDA, elevating the agency’s profile and validating rigorous pre-market drug testing.
In recognition of her actions, President John F. Kennedy awarded Kelsey the President’s Award for Distinguished Federal Civilian Service in August 1962, the highest honor a civilian can receive in U.S. government service. The crisis directly catalyzed the passage of the Kefauver-Harris Drug Amendments of 1962, signed into law by President Kennedy. According to federal legislative archives, the new law required pharmaceutical companies to prove both the safety and efficacy of new drugs before marketing them, informed consent for clinical trial participants, and immediate reporting of adverse drug reactions to the FDA.